What is the incidence of L-asparaginase–induced thrombosis during treatment of acute lymphoblastic leukemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

L-Asparaginase-Induced Thrombosis Incidence in ALL

The incidence of L-asparaginase-induced thrombosis during ALL treatment ranges from 5-11% in pediatric patients and 10-34% in adults, with the highest rates occurring in adults over 30 years of age.

Age-Stratified Incidence Rates

The thrombosis risk is dramatically age-dependent:

  • Pediatric patients (0-18 years): 5% overall incidence 1
  • Adolescent and young adults (AYA, 15-39 years): 11.2% 2
  • Adults (18-50 years): 34% overall 1
  • Adults >30 years: 42% - representing the highest risk group 1

Age is the single most significant predictor of thrombotic events 1. The steep increase in thrombosis rates after age 18 reflects both physiological differences in drug metabolism and higher body surface area requiring larger asparaginase doses 3.

Timing and Location of Thrombotic Events

Treatment Phase Distribution

  • Induction phase: 44-86% of thrombotic events occur during this period 2, 4
  • Median time to symptoms: 21 days from first L-asparaginase exposure 4
  • Events can occur as early as 2 days or as late as 27 days after initiation 4

Anatomical Sites

  • All events are venous (arterial thrombosis is rare) 2
  • Cerebral venous sinus thrombosis (CSVT): 1.5-1.6% incidence, representing 41% of all thrombotic events 2, 4, 1
  • Deep vein thrombosis and pulmonary embolism comprise the remainder 2, 5

High-Risk Populations

Pediatric Risk Factors

The following factors significantly increase thrombosis risk in children:

  • Age ≥10 years (p ≤ 0.0004) 6
  • Mediastinal mass (p ≤ 0.0004) 6
  • Non-O blood type (p ≤ 0.0004) 6
  • Overweight/obesity (p ≤ 0.0004) 6

Adult Risk Factors

  • Age ≥40 years: AOR 10.4 (95% CI 1.47-75.0, p=0.019) 2
  • Time to complete remission >4 weeks: AOR 4.8 (95% CI 1.10-20.72, p=0.037) 2
  • T-cell immunophenotype: Higher rates than B-cell ALL (p<0.0001) 6

Laboratory Marker

Fibrinogen <50 mg/dL serves as a specific marker for hypercoagulability:

  • Specificity: 90%
  • Relative risk: 10 (p=0.014)
  • 25% of patients with fibrinogen <50 mg/dL develop thrombosis 7

Formulation-Specific Differences

Pegylated asparaginase (PEG-ASP) carries significantly higher thrombotic risk than native L-ASP 8:

Induction Phase

  • L-ASP: 10.29% VTE rate
  • PEG-ASP: 28.57% VTE rate (OR 3.35,95% CI 1.51-7.39, p=0.0035)

Intensification Phase

  • L-ASP: 13.64% VTE rate
  • PEG-ASP: 34.37% VTE rate (OR 3.96,95% CI 1.57-9.96, p=0.0096)

This 3-4 fold increased risk persists despite prophylactic anticoagulation 8.

Clinical Impact and Mortality

Mortality Rates

  • Thrombosis-attributable mortality: 28-47% in patients who develop thrombotic events 2, 4
  • In resource-limited settings, 29.4% of deaths in patients with thrombosis are directly attributed to the thrombotic event 2
  • Critical caveat: Despite the high mortality from thrombosis itself, overall event-free survival at 48 months remains similar between patients with and without VTE (85% vs 88%, p=0.36) 1

Recurrence Risk

  • Overall recurrence rate: 33% 1
  • Pediatric patients: 17% recurrence
  • Adult patients: 47% recurrence (p=0.07) 1

Thromboprophylaxis Considerations

While the 2022 ITAC guidelines note that methodological limitations in 23 non-randomized studies preclude definitive treatment effect estimates 9, one retrospective study showed LMWH prophylaxis reduced VTE incidence (OR 0.21-0.83) without increasing major bleeding 9.

Key management principle: After VTE occurs, asparaginase can be safely restarted with closely monitored anticoagulation once imaging demonstrates clot stabilization or improvement. With this approach, 70% of patients ultimately receive ≥85% of intended asparaginase doses 1.

Common Pitfalls

  • Gender and corticosteroid use are not significant predictors of thrombosis 6
  • Prophylactic anticoagulation does not eliminate risk, particularly with PEG-ASP 8
  • CSVT has high case fatality (28%) but survivors typically achieve complete neurological recovery 4

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.